Nathan Brown

Nathan Brown

Akin Gump Strauss Hauer & Feld LLP

Contact  |  View Bio  |  RSS

Latest Publications

Share:

FDA Issues Additional Guidance Documents for Compounding Pharmacies and Outsourcing Facilities; Addresses Repackaging

The U.S. Food and Drug Administration (FDA) announced the availability of four new Draft Guidance documents and a draft Memorandum of Understanding (MOU) between the FDA and individual states. The Draft Guidance documents...more

2/20/2015 - Biologics DQSA Draft Guidance Drug Compounding Drug Manufacturers FDA FDCA Outsourcing Pharmaceutical Pharmaceutical Manufacturers Pharmacies Premarket Approval Applications Prescription Drugs

FDA Proposes Additional Flexibility for Mobile Health Products

Draft Guidances Address General Wellness Products and Device Accessories - The U.S. Food and Drug Administration (FDA or “the Agency”) has announced two more key parameters of its regulatory approach to mobile health...more

1/21/2015 - Draft Guidance FDA Healthcare Medical Devices mHealth Wellness Programs

FDA Issues Three Guidance Documents for Outsourcing Facilities

FDA has announced the availability of two Final Guidance documents and one revised Draft Guidance related to Section 503B outsourcing facilities. FDA published the three guidance documents Friday afternoon. The Final...more

11/25/2014 - Draft Guidance Drug Compounding FDA FDCA Final Guidance Outsourcing Facilities Pharmacies Registration Reporting Requirements Section 503

IMDRF Releases International Framework for Regulating Device Software

On October 14, 2014, the International Medical Device Regulators Forum (IMDRF) issued a final version of “Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations” (“the...more

10/20/2014 - Biotechnology FCC FDA Medical Devices ONC

FDA Takes First Steps Towards Regulating Laboratory Developed Tests

On July 31, the Food and Drug Administration (FDA or “the Agency”) notified Congress that it intends to issue draft guidance proposing a Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) (“Draft...more

8/14/2014 - CLIA Clinical Laboratories Diagnostic Tests FDA Medical Devices

FDA Accepts First Biosimilar Application under New Approval Pathway

July 24, 2014 was a landmark day in the biotechnology industry: Sandoz (the generic arm of Novartis) announced that the U.S. Food and Drug Administration (FDA or “the Agency”) had accepted the first application for a U.S....more

7/29/2014 - Biologics Biologics Price Competition and Innovation Act of 2009 Biosimilars FDA Patents Pharmaceutical Pharmaceutical Patents Prescription Drugs

Drug Compounding: Manufacturing Standards Announced for Outsourcing Facilities

In late 2013, Congress passed the Drug Quality and Security Act (DQSA) in response to a deadly fungal meningitis outbreak linked to a sterile compounded injectable drug shipped across the country and responsible for more than...more

7/3/2014 - CGMP DQSA Drug Compounding Drug Manufacturers FDA Manufacturers Outsourcing Pharmaceutical Prescription Drugs

7 Results
|
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×